Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Minder stadium III/IV-longkanker door bloedtest plus lagedosis-CT?
mei 2021 | Longoncologie